Immunotherapy: A new paradigm shift in the treatment of advanced NSCLC

Speaker: Marina Garassino

In an ESMO expert interview, M. Garassino discusses the practice changing data presented at 2015 ASCO Annual Meeting with PD-1 blockade across NSCLC histologies. In particular, she elaborates data from the CheckMate 017 in squamous cell NSCLC and a twin CheckMate 057 study in non-squamous cell NSCLC; the toxicities of nivolumab were reversible and better than with docetaxel , the current standard of care. In addition she discusses the other immunotherapy data, an emerging and rapidly evolved field of research in the NSCLC treatment.

Discussion Points

  • Advanced non-squamous NSCLC: nivolumab vs docetaxel in CheckMate 057
  • Anti-PD-L1: New findings in a phase II study
  • Preliminary data from KEYNOTE-021 cohort D are promising
  • A new paradigm for the treatment of NSCLC